Kangpu Biopharmaceuticals, Ltd. announced today that the Center for Drug Evaluation (CDE) of China's National Medical ...

In the Phase IIa clinical study in SLE patients completed in the US, KPG-818 was well tolerated and demonstrated promising preliminary efficacy in SLE patients with cutaneous manifestations.

Antolin J, Amerigo MJ, Cantabrana A, Roces A, Jimenez P: Systemic lupus erythematosus: clinical manifestations and immunological parameters in 194 patients. Subgroup classification of SLE.

In April 2025, Pfizer organized a study is to learn about the effects, safety and how PF-06823859 is processed in adults with ...

Uncommon Presentations A higher prevalence of more uncommon manifestations of SLE, such as gastrointestinal ... associating with different clinical courses (mild disease with no major organ ...

Q1 2025 Earnings Call Transcript May 9, 2025 Kymera Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.82, expectations were $-0.92. Justine Koenigsberg: Good morning, and welcome to ...